Literature DB >> 10442571

Determinants of circulating insulin-like growth factor-I.

K Hall1, A Hilding, M Thorén.   

Abstract

Total IGF-I level in serum is a sensitive index during growth hormone (GH) replacement therapy of adults, since GH stimulates the hepatic expressions of both insulin-like growth factor (IGF-I) and acid-labile subunit (ALS) and the major part of IGF-I in the circulation is found in a ternary complex together with ALS and IGFBP-3. However, other regulators of the proteins constituting the ternary complex may influence IGF-I levels. In healthy subjects the serum IGF-I levels are low at birth, rise during childhood, with peak levels during puberty, and decline with increasing age. This pattern has been attributed to the age-dependent GH production, but it is unknown whether the wide range of IGF-I levels within each age interval is due to GH production or GH sensitivity. In elderly twins approximately 60% of IGF-I levels are genetically determined. The remaining environmental dependency of IGF-I is partly due to nutrition. Both caloric and protein content of the diet is of importance. Thus, low IGF-I levels are found in GH deficient patients as well as in patients with GH resistance due to malnutrition or GH receptor defects. It is essential that IGF-I determination is performed by assays in which IGFBPs do not interfere, and that IGF-I concentration is evaluated in relation to age, i.e. expressed in SD score, and the number of individuals constituting the reference intervals improves the sensitivity and specificity. Although determination of IGF-I is recommended in assessing GH deficiency in children, its diagnostic value in patients with adult onset of GH deficiency is not agreed upon. In the age group above 40-80 years many patients with pituitary/hypothalamic disorders and GH peaks below 3 microg/l during provocation tests have normal IGF-I levels. It is not clarified, whether the IGF-I levels within normal range for age is due to endogenous basal GH production being sufficient or other factors stimulating IGF-I, IGFBP-3 or ALS expressions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10442571

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  17 in total

1.  Normal IGF-I and enhanced IGFBP-3 response to very low rhGH dose in patients with dilated cardiomyopathy.

Authors:  F Broglio; A Benso; E Arvat; G Aimaretti; C Gottero; R Granata; M F Boghen; M Bobbio; F Camanni; E Ghigo
Journal:  J Endocrinol Invest       Date:  2000-09       Impact factor: 4.256

2.  A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians.

Authors:  Fredrick R Schumacher; Iona Cheng; Matthew L Freedman; Lorelei Mucci; Naomi E Allen; Michael N Pollak; Richard B Hayes; Daniel O Stram; Federico Canzian; Brian E Henderson; David J Hunter; Jarmo Virtamo; Jonas Manjer; J Michael Gaziano; Laurence N Kolonel; Anne Tjønneland; Demetrius Albanes; Eugenia E Calle; Edward Giovannucci; E David Crawford; Christopher A Haiman; Peter Kraft; Walter C Willett; Michael J Thun; Loïc Le Marchand; Rudolf Kaaks; Heather Spencer Feigelson; H Bas Bueno-de-Mesquita; Domenico Palli; Elio Riboli; Eiliv Lund; Pilar Amiano; Gerald Andriole; Alison M Dunning; Dimitrios Trichopoulos; Meir J Stampfer; Timothy J Key; Jing Ma
Journal:  Hum Mol Genet       Date:  2010-05-19       Impact factor: 6.150

3.  Associations between genetic polymorphisms of insulin-like growth factor axis genes and risk for age-related macular degeneration.

Authors:  Chung-Jung Chiu; Yvette P Conley; Michael B Gorin; Gary Gensler; Chao-Qiang Lai; Fu Shang; Allen Taylor
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-25       Impact factor: 4.799

4.  Impairment of GH secretion in adults with primary empty sella.

Authors:  M Gasperi; G Aimaretti; E Cecconi; A Colao; C Di Somma; S Cannavò; C Baffoni; M Cosottini; L Curtò; F Trimarchi; G Lombardi; L Grasso; E Ghigo; E Martino
Journal:  J Endocrinol Invest       Date:  2002-04       Impact factor: 4.256

5.  Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer.

Authors:  Fangyi Gu; Fredrick R Schumacher; Federico Canzian; Naomi E Allen; Demetrius Albanes; Christine D Berg; Sonja I Berndt; Heiner Boeing; H Bas Bueno-de-Mesquita; Julie E Buring; Nathalie Chabbert-Buffet; Stephen J Chanock; Françoise Clavel-Chapelon; Vanessa Dumeaux; J Michael Gaziano; Edward L Giovannucci; Christopher A Haiman; Susan E Hankinson; Richard B Hayes; Brian E Henderson; David J Hunter; Robert N Hoover; Mattias Johansson; Timothy J Key; Kay-Tee Khaw; Laurence N Kolonel; Pagona Lagiou; I-Min Lee; Loic LeMarchand; Eiliv Lund; Jing Ma; N Charlotte Onland-Moret; Kim Overvad; Laudina Rodriguez; Carlotta Sacerdote; Maria-José Sánchez; Meir J Stampfer; Pär Stattin; Daniel O Stram; Gilles Thomas; Michael J Thun; Anne Tjønneland; Dimitrios Trichopoulos; Rosario Tumino; Jarmo Virtamo; Stephanie J Weinstein; Walter C Willett; Meredith Yeager; Shumin M Zhang; Rudolf Kaaks; Elio Riboli; Regina G Ziegler; Peter Kraft
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-09-01       Impact factor: 4.254

6.  Body size in early life and adult levels of insulin-like growth factor 1 and insulin-like growth factor binding protein 3.

Authors:  Elizabeth M Poole; Shelley S Tworoger; Susan E Hankinson; Eva S Schernhammer; Michael N Pollak; Heather J Baer
Journal:  Am J Epidemiol       Date:  2011-08-09       Impact factor: 4.897

7.  Primary hyperparathyroidism is associated with an impaired secretion of growth hormone but not of the other anterior pituitary hormones.

Authors:  E Cecconi; M Gasperi; L Grasso; M Genovesi; G Aimaretti; F Broglio; L Bartalena; C Marcocci; E Martino
Journal:  J Endocrinol Invest       Date:  2002-03       Impact factor: 4.256

8.  Three-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diagnosis of acromegaly.

Authors:  S Grottoli; P Razzore; D Gaia; M Gasperi; M Giusti; A Colao; E Ciccarelli; V Gasco; E Martino; E Ghigo; F Camanni
Journal:  J Endocrinol Invest       Date:  2003-02       Impact factor: 4.256

Review 9.  Pitfalls in the biochemical assessment of acromegaly.

Authors:  Pamela U Freda
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

10.  Salivary free insulin-like growth factor-i levels: effects of an acute physical exercise in athletes.

Authors:  G Antonelli; R Gatti; M Prearo; E F De Palo
Journal:  J Endocrinol Invest       Date:  2009-01       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.